Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Matrix Clinical Research Inc

Neither a doctor nor a teaching hospital

Research payments

$9,061,843

756 payments

Through program year 2025, Matrix Clinical Research Inc is reported as receiving $9,061,843 in research payments, across 756 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,006,496 157
2024 Research $295,473 29
2023 Research $1,145,455 87
2022 Research $2,987,223 207
2021 Research $3,017,279 218
2020 Research $439,703 49
2019 Research $170,215 9

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pfizer Inc. $3,345,630 195 payments
  2. GlaxoSmithKline, LLC. $2,414,621 277 payments
  3. Abbott Laboratories $1,248,438 26 payments
  4. Moderna TX, Inc. $889,018 142 payments
  5. Evofem Biosciences, Inc. $559,936 51 payments
  6. Organon LLC $326,893 29 payments
  7. Mylan Inc. $165,263 24 payments
  8. Merck Sharp & Dohme Corporation $76,722 5 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $35,321 7 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3 Randomized Doubleblinded Placebocontrolled Trial to Evaluate the Efficacy and Safety of A Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Infants Born to Women Vaccinated During Pregnancy $1,821,931 63 payments
  2. A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi-Countr $886,150 107 payments
  3. Clinical Evaluation of the Investigational ID NOW COVID-19 Assay $882,242 7 payments
  4. Phase 1 Openlabel Dosefinding Study to Evaluate Safety Tolerability and Immunogenicity and Phase 23 Placebocontrolled Observerblinded Safety Tolerability and Immunogenicity Study of A Sarscov2 Rna Vaccine Candidate Against Covid19 in Healthy Children and Young Adults $793,001 28 payments
  5. Study name not reported $643,502 106 payments
  6. A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis $592,690 69 payments
  7. A Phase 2, Randomized, Double-Blind, Multi-Dose, Dose Finding Study to $314,507 23 payments
  8. A Phase II, Observer-Blind, Randomized, Controlled Study to Evaluate T $312,218 16 payments
  9. A Phase 2 Placebocontrolled Randomized Proof of Concept Study of A Respiratory Syncytial Virus RSV Vaccine in Pregnant Women $309,909 27 payments
  10. A Phase 23 Placebocontrolled Randomized Observerblind Study to Evaluate the Safety Tolerability and Immunogenicity of A Sarscov2 Rna Vaccine Candidate Bnt162b2 Against Covid19 in Healthy Pregnant Women 18 Years of Age and Older $298,768 34 payments
What the money was spent on Research payments · program years 2019–2025
  1. Professional salary support $528,554 49 payments
  2. Patient care $326,893 29 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record